MSLN and triple-negative breast carcinoma: With the goal of overcoming PD-L1 effects on CAR-T cells, Hu et al. evaluated an anti-mesothelin second generation CAR-T cell with knocked down PD-1 against mesothelin positive triple negative breast cancer (TNBC) cells.